---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-028289"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:29:15.197716+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma Q2 revenue $10.9M (+6% YoY); net income $0.9M

## Summary
- Q2 net revenue $10.9M (+6% vs prior year, +18% sequential); YTD revenue $20.1M.
- Q2 net income $0.9M ($0.06/diluted share); YTD net income $1.1M ($0.07/share).
- Adjusted Q2 earnings $2.3M ($0.16/share); YTD adjusted $4.0M ($0.27/share).
- FDA approved Caldolor for infants (3-6 months) in May; study results published June.
- Received $2.8M in FDA barrier-to-innovation fee waivers in June 2023.

## SEC filing metadata
- accession: 0001628280-23-028289
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023028289/0001628280-23-028289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023028289/cpix-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-028289
- JSON: https://secwatch.observer/filing/0001628280-23-028289.json
- Plain text: https://secwatch.observer/filing/0001628280-23-028289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.